OBJECTIVES:  The HIV infection rises, by number of infected people, and by worldwide spreading of infection. Increasing number of infected people and incoming of expensive and high-active antiretrovirals result in growth of costs for pharmacotherapy of public health insurance money. The aim of the study was 1. to define epidemiology of the spreading HIV infection, incidence and prevalence in Slovakia and in European Economic Area countries within 2004–2014; 2. to cover information about utilisation of antiretrovirals in Slovakia during tracking period. METHODS:  Publicly available data analysis on: 1. epidemiological trends in Slovakia and in Europe from Slovak National Health Information Centre, ECDC and WHO papers; 2. the consumption of antiretrovirals ATC group J05 within the period 2004-2014 from Slovak State Institute for Drug Control database. RESULTS:  The incidence of infection has been increased more than 4-fold during 2004 -2014 in Slovakia. The prevalence of HIV by the end of the year 2014 was 595 cases, and is increasing. 78 people are in AIDS phase of infection, it makes 13 % of infected people. The mortality has increased near to 2-fold during tracking period. The consumption of antiretrovirals in 2004 and 2014 was 827,205 DDD and 3 235,139 DDD, respectively. The J05AF subgroup of antiretrovirals with its rate 0,15 % (16 841,160 €) had the highest rate on the consumption among all products in Slovakia. The J05AG subgroup of antiretrovirals has the lowest rate on the consumption with its 0.01 % (1 333,680 €) rate. The costs for pharmacotherapy of one infected person in 2004 and 2014 were 15,445 € and 21,993 € respectively. It makes growth of public health insurance costs by 42.40 %. CONCLUSIONS:  The continuous analysis and data of incidence, prevalence and utilisation of antiretrovirals are needed for prediction of infection growth, and rational allocation of health care financing.